Do regional differences in adipocyte biology provide new pathophysiological insights?

Trends in Pharmacological Sciences

Volumn 24, Issue 6, 2003, Pages 276-283

  Lafontan, Max ^a   Berlan, Michel ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; ADIPONECTIN; ALPHA 2 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; CYTOKINE; FATTY ACID; HORMONE; INSULIN; INTERLEUKIN 6; ISOPRENALINE; LEPTIN; PHENTOLAMINE; POLYPEPTIDE; RESISTIN; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADRENERGIC SYSTEM; CELL ISOLATION; CYTOKINE PRODUCTION; CYTOLOGY; DRUG EFFECT; DRUG RECEPTOR BINDING; GENETIC HETEROGENEITY; HORMONE SYNTHESIS; HUMAN; LIPID METABOLISM; LIPOLYSIS; OBESITY; PATHOPHYSIOLOGY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT; VISCERA;

EID: 0038341767     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(03)00132-9     Document Type: Review

References (87)

1. Montague C.T., O'Rahilly S. The perils of portliness. Causes and consequences of visceral adiposity. Diabetes. 49:2000;883-888.
2. Wajchenberg B.L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr. Rev. 21:2000;697-738.
3. Björntorp P. 'Portal' adipose tissue as a generator of risks factors for cardiovascular disease and diabetes. Arteriosclerosis. 10:1990;493-496.
4. Ravussin E., Smith S.R. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation results in ectopic fat storage, insulin resistance and type 2 diabetes mellitus. Ann. New York Acad. Sci. 967:2002;363-378.
5. Trayhurn P., Beattie J.H. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc. Nutr. Soc. 60:2001;329-339.
6. Boden G. Interaction between free fatty acids and glucose metabolism. Curr. Opin. Clin. Nutr. Metab. Care. 5:2002;545-549.
7. Jouven X., et al. Circulating non-esterified fatty acid level as a predictive risk factor for sudden death in population. Circulation. 104:2001;756-761.
8. Bergman R.N., Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol. Metab. 11:2000;351-356.
9. McGarry J.D. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 51:2002;7-18.
10. Steinberg H.O., Baron A.D. Vascular function, insulin resistance and fatty acids. Diabetologia. 45:2002;623-634.
11. Yu C., et al. Mechanisms by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277:2002;50230-50236.
12. Lefebvre A.-M., et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes. 47:1998;98-103.
13. Zierath J., et al. Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. Diabetologia. 41:1998;1343-1354.
14. Wu X., et al. Depot-specific variation in protein-tyrosine phosphatase activities in human omental and subcutaneous adipose tissue: a potential contribution to differential insulin sensitivity. J. Clin. Endocrinol. Metab. 86:2001;5973-5980.
15. Meek S.E., et al. Insulin regulation of regional free fatty acid metabolism. Diabetes. 48:1999;10-14.
16. Guo Z., et al. Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes. 48:1999;1586-1592.
17. Basu A., et al. Systemic and regional free fatty acid metabolism in type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 280:2001;E1000-E1006.
18. Langin D., et al. Millenium fat-cell lipolysis reveals unsuspected novel tracks. Horm. Metab. Res. 32:2000;443-452.
19. Konkar A.A., et al. β1-adrenergic receptors mediate β3-adrenergic-independent effects of CGP12177. Mol. Pharmacol. 57:2000;252-258.
20. Lönnqvist F., et al. Catecholamine-induced lipolysis in adipose tissue of the elderly. J. Clin. Invest. 85:1990;1614-1621.
21. 2-adrenoceptors: the regulation of fat cell function and lipolysis. Endocr. Rev. 16:1995;716-738.
22. Jensen M.D. Lipolysis: contribution from regional fat. Annu. Rev. Nutr. 17:1997;127-139.
23. Arner P. Catecholamine-induced lipolysis in obesity. Int. J. Obes. Relat. Metab. Disord. 23:1999;10-13.
24. Mauriège P., et al. Heterogeneous distribution of beta- and alpha2-adrenoceptor binding sites in human fat cells from various fat deposits: functional consequences. Eur. J. Clin. Invest. 17:1987;156-165.
25. Garenc C., et al. The alpha2-adrenergic receptor gene and body fat content and distribution: the HERITAGE family Study. Mol. Med. 8:2002;88-94.
26. Schiffelers S.L.H., et al. In vivo β3-adrenergic stimulation of human thermogenesis and lipid utilization. Clin. Pharmacol. Ther. 67:2000;558-566.
27. Enevoldsen L., et al. In vivo human lipolytic activity in preperitoneal and subdivisions of subcutaneous abdominal adipose tissue. Am. J. Physiol. 281:2001;E1110-E1114.
28. Stich V., et al. Activation of antilipolytic α2-adrenergic receptors by epinephrine during exercise in human adipose tissue. Am. J. Physiol. 277:1999;R1076-R1083.
29. Stallknecht B., et al. Role of the sympathoadrenergic system in adipose tissue metabolism during exercise in humans. J. Physiol. 536:2001;283-294.
30. Stich V., et al. Activation of alpha2-adrenergic receptors impairs exercise-induced lipolysis in SCAT of obese subjects. Am. J. Physiol. 279:2000;R499-R504.
31. De Glisezinski I., et al. Lack of alpha2-adrenergic antilipolytic effect during exercise in subcutaneous adipose tissue of trained men. J. Appl. Physiol. 91:2001;1760-1765.
32. Stich V., et al. Hypocaloric diet reduces exercise-induced alpha2-adrenergic antilipolytic effect and alpha2-adrenergic receptor mRNA levels in adipose tissue of obese women. J. Clin. Endocrinol. Metab. 87:2002;1274-1281.
33. Patel J.N., et al. Norepinephrine spillover from human adipose tissue before and after a 72-hour fast. J. Clin. Endocrinol. Metab. 87:2002;3373-3377.
34. Jensen M.D. Adipose tissue and fatty acid metabolism in humans. J. R. Soc. Med. 95:2002;3-7.
35. Nielsen S., et al. Energy expenditure, sex, and endogenous fuel availability in humans. J. Clin. Invest. 111:2003;981-988.
36. Hotasmiligil G.S., et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNFα- and obesity-induced insulin resistance. Science. 271:1996;665-668.
37. Uysal K.T., et al. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature. 389:1997;610-614.
38. Löfgren P., et al. Secretion of tumor necrosis factor-α shows a strong relationship to insulin-stimulated glucose transport in human adipose tissue. Diabetes. 49:2000;688-692.
39. Xu H., et al. Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity. Diabetes. 51:2002;1876-1883.
40. Margetic S., et al. Leptin: a review of its peripheral actions and interactions. Int. J. Obes. Relat. Metab. Disord. 26:2002;1407-1433.
41. Montague C.T., et al. Depot and sex-specific differences in human leptin mRNA expression. Implications for the control of regional fat distribution. Diabetes. 46:1997;342-347.
42. van Harmelen V., et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes. 47:1998;913-917.
43. van Harmelen V., et al. Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes. 51:2002;2029-2036.
44. Weyer C., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86:2001;1930-1935.
45. Stefan N., et al. Plasma adiponectin concentrations in children: Relationship with obesity and insulinemia. J. Clin. Endocrinol. Metab. 87:2002;4652-4656.
46. Motoshima H., et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J. Clin. Endocrinol. Metab. 87:2002;5662-5667.
47. Steppan C., et al. The hormone resistin links obesity to diabetes. Nature. 409:2001;307-312.
48. Steppan C.M., Lazar M.A. Resistin and obesity-associated insulin resistance. Trends Endocrinol. Metab. 13:2002;18-23.
49. Rajala M.W., et al. Adipose tissue-derived resistin and gut-derived resistin-like molecule-β selectively impair insulin action on glucose production. J. Clin. Invest. 111:2003;225-230.
50. Fried S.K., et al. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoids. J. Clin. Endocrinol. Metab. 83:1998;847-850.
51. Delporte M.-L., et al. Pre- and post-translational negative effect of β-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem. J. 367:2002;677-685.
52. Bergman M. Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia. 43:2000;946-952.
53. Gabriely I., et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging. An adipokine-mediated process? Diabetes. 51:2002;2951-2958.
54. Thorne A., et al. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int. J. Obes. Relat. Metab. Disord. 26:2002;193-199.
55. Berlan M., et al. Pharmacological prospect for alpha2-adrenoceptor antagonist therapy. Trends Pharmacol. Sci. 13:1992;277-282.
56. Fruebis J., et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. U. S. A. 98:2001;2005-2010.
57. Ross R., et al. Sex differences in lean and adipose tissue distribution by magnetic resonance imaging. Am. J. Clin. Nutr. 59:1994;1277-1285.
58. Reynisdottir S., et al. Comparison of hormone-sensitive lipase activity in visceral and subcutaneous human adipose tissue. J. Clin. Endocrinol. Metab. 82:1997;4162-4166.
59. Edens N.K., et al. In vitro lipid synthesis in human adipose tissue from three abdominal sites. Am. J. Physiol. 265:1993;E374-E379.
60. Vikman H.-L., Ohisalo J.J. Regulation of adenylate cyclase in plasma membranes of human intraabdominal and abdominal subcutaneous adipocytes. Metabolism. 42:1993;739-742.
61. Mauriège P., et al. Regional variation in adipose tissue lipolysis in lean and obese men. J. Lipid Res. 32:1991;1625-1633.
62. Mauriège P., et al. Regional differences in adipose tissue lipolysis from lean and obese women: existence of postreceptor alterations. Am. J. Physiol. 269:1995;E341-E350.
63. van Harmelen V., et al. Noradrenaline-induced lipolysis in isolated mesenteric, omental and subcutaneous adipocytes from obese subjects. Int. J. Obes. Relat. Metab. Disord. 21:1997;972-979.
64. Arner P., et al. Beta-adrenoceptor expression in human fat cells from different regions. J. Clin. Invest. 86:1990;1595-1600.
65. Hellmer J., et al. Mechanism for differences in lipolysis between human subcutaneous and omental fat cells. J. Clin. Endocrinol. Metab. 75:1992;15-20.
66. Lafontan M., et al. Alpha-adrenergic antilipolytic effect of epinephrine in human fat cells of the thigh: comparison with epinephrine responsiveness of different fat deposits. Eur. J. Clin. Invest. 9:1979;261-266.
67. 2A-adrenergic regulation of cyclic AMP accumulation and lipolysis in human omental and subcutaneous adipocytes. Int. J. Obes. 20:1996;185-189.
68. Fisher R.M., et al. Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia. 44:2001;1268-1273.
69. Fisher R.M., et al. Fatty acid binding protein expression in different human adipose tissue depots in relation to rates of lipolysis and insulin concentration in obese individuals. Mol. Cell. Biochem. 239:2002;95-100.
70. Bolinder J., et al. Differences at the receptor and post-receptor level between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis. Diabetes. 32:1983;117-123.
71. Fried S.K., et al. Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues from obese women and men. J. Clin. Invest. 92:1993;2191-2198.
72. Caserta F., et al. Fat depot origin affects fatty acid handling in cultured rat and human preadipocytes. Am. J. Physiol. 280:2001;E238-E247.
73. Dusserre E., et al. Differences in mRNA expression of the protein secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim. Biophys. Acta Mol. Cell. Res. 1500:2000;88-96.
74. Salter A.M., et al. Regional variation in high density lipoprotein binding to human adipocyte plasma membranes of massively obese subjects. Eur. J. Clin. Invest. 17:1987;16-22.
75. Hube F., et al. Difference in leptin mRNA levels between omental and subcutaneous adipose tissues from obese humans. Horm. Metab. Res. 28:1996;690-693.
76. Gottschling-Zeller H., et al. Effect of tumor necrosis α and tranforming growth factor β1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture. Metabolism. 49:2000;666-671.
77. Bastelica D., et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat. Evidence of differences between visceral and subcutaneous deposits. Arterioscler. Thromb. Vasc. Biol. 22:2002;173-178.
78. Bujalska I.J., et al. Does central obesity reflect 'Cushing disease of the omentum'? Lancet. 349:1997;1210-1213.
79. van Harmelen V., et al. The association of human adipose tissue angiotensinogen gene expression with abdominal fat distribution in obesity. Int. J. Obes. Relat. Metab. Disord. 24:2000;673-678.
80. Joyner J., et al. Intrinsic regional differences in androgen receptors and dihydrotestosterone metabolism in human preadipocytes. Horm. Metab. Res. 34:2002;223-228.
81. Rebuffe-Scrive M., et al. Steroid hormone receptors in human adipose tissues. J. Clin. Endocrinol. Metab. 71:1990;1215-1219.
82. Montague C.T., et al. Depot-related expression in human subcutaneous and omental adipocytes. Diabetes. 47:1998;1384-1391.
83. Niesler C.U., et al. Human preadipocytes display a depot-specific susceptibility to apoptosis. Diabetes. 47:1998;1365-1368.
84. Ryden M., et al. Increased expression of eNOS protein in omental versus subcutaneous adipose tissue in obese human subjects. Int. J. Obes. 25:2001;811-815.
85. Tchkonia T., et al. Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. Am. J. Physiol. 282:2002;R1286-R1296.
86. Adams M., et al. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J. Clin. Invest. 100:1997;3149-3153.
87. Sewter C., et al. Regional differences in the response of human pre-adipocytes to PPARγ and RXRα agonists. Diabetes. 51:2002;718-723.